Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism

Nature Chemical Biology

Volumn 9, Issue 2, 2013, Pages 97-104

  Gut, Philipp ^a,b   Baeza Raja, Bernat ^c   Andersson, Olov ^a,b,g,h   Hasenkamp, Laura ^a,b   Hsiao, Joseph ^a,b   Hesselson, Daniel ^a,b,g,i   Akassoglou, Katerina ^c   Verdin, Eric ^a,d   Hirschey, Matthew D ^a,d,e,f   Stainier, Didier Y R ^a,b,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

ⁱ MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BECLOMETASONE; BUDESONIDE; CLOMIPRAMINE; CLOZAPINE; DEXAMETHASONE; DOXEPIN; FLUOXETINE; FORMOTEROL; ISOPRENALINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; RO 54864; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIET RESTRICTION; FATTY LIVER; GENE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HIGH THROUGHPUT SCREENING; LIPID DIET; METABOLIC REGULATION; NONHUMAN; OBESITY; PCK1 GENE; PRIORITY JOURNAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BENZODIAZEPINONES; DRUG DESIGN; FASTING; FOOD DEPRIVATION; GLUCONEOGENESIS; GLUCOSE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOQUINOLINES; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN TRANSPORT; TRANSGENES; ZEBRAFISH;

DANIO RERIO; MUS;

EID: 84872681212     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1136     Document Type: Article

References (51)

1. Mackay, J. & Mensah, G.A. Deaths from coronary heart disease. in The Atlas of Heart Disease and Stroke. 48-49 (World Health Organization, 2008).
2. Haslam, D.W. & James, W.P.T. Obesity. Lancet 366, 1197-1209 (2005).
3. Muoio, D.M. & Newgard, C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9, 193-205 (2008).
4. Taubes, G. Insulin resistance. Prosperity's plague. Science 325, 256-260 (2009).
5. Baur, J.A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342 (2006).
6. Tseng, Y.-H., Cypess, A.M. & Kahn, C.R. Cellular bioenergetics as a target for obesity therapy. Nat. Rev. Drug Discov. 9, 465-482 (2010).
7. Silber, B.M. Driving drug discovery: the fundamental role of academic labs. Sci. Transl. Med. 2, 30cm16 (2010).
8. Swinney, D.C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519 (2011).
9. Zon, L.I. & Peterson, R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4, 35-44 (2005).
10. Schlegel, A. & Stainier, D.Y.R. Lessons from 'lower' organisms: what worms, flies, and zebrafish can teach us about human energy metabolism. PLoS Genet. 3, e199 (2007).
11. Yang, J., Reshef, L., Cassuto, H., Aleman, G. & Hanson, R.W. Aspects of the control of phosphoenolpyruvate carboxykinase gene transcription. J. Biol. Chem. 284, 27031-27035 (2009).
12. Lin, H.V. & Accili, D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 14, 9-19 (2011).
13. Burgess, S.C. et al. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab. 5, 313-320 (2007).
14. Kurita, R. et al. Suppression of lens growth by αA-crystallin promoter-driven expression of diphtheria toxin results in disruption of retinal cell organization in zebrafish. Dev. Biol. 255, 113-127 (2003).
15. Liu, Y. et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456, 269-273 (2008).
16. Eisenstein, A.B. Current concepts of gluconeogenesis. Am. J. Clin. Nutr. 20, 282-289 (1967).
17. Croniger, C.M. et al. Mice with a deletion in the gene for CCAAT/enhancer-binding protein β have an attenuated response to cAMP and impaired carbohydrate metabolism. J. Biol. Chem. 276, 629-638 (2001).
18. Foretz, M. et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355-2369 (2010).
19. Gonzalez-Polo, R.-A. et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 24, 7503-7513 (2005).
20. Rupprecht, R. et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 9, 971-988 (2010).
21. Hirsch, J.D., Beyer, C.F., Malkowitz, L., Loullis, C.C. & Blume, A.J. Characterization of ligand binding to mitochondrial benzodiazepine receptors. Mol. Pharmacol. 35, 164-172 (1989).
22. Marangos, P.J., Patel, J., Boulenger, J.P. & Clark-Rosenberg, R. Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864. Mol. Pharmacol. 22, 26-32 (1982).
23. Rakhshandehroo, M., Hooiveld, G., Müller, M. & Kersten, S. Comparative analysis of gene regulation by the transcription factor PPARα between mouse and human. PLoS ONE 4, e6796 (2009).
24. Kersten, S. et al. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489-1498 (1999).
25. Anson, R.M. et al. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc. Natl. Acad. Sci. USA 100, 6216-6220 (2003).
26. Rupprecht, R. et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490-493 (2009).
27. Fulda, S., Galluzzi, L. & Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447-464 (2010).
28. Verma, A., Nye, J.S. & Snyder, S.H. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc. Natl. Acad. Sci. USA 84, 2256-2260 (1987).
29. Papadopoulos, V. et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402-409 (2006).
30. Braestrup, C. & Squires, R.F. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc. Natl. Acad. Sci. USA 74, 3805-3809 (1977).
31. Song, Y. et al. CRTC3 links catecholamine signalling to energy balance. Nature 468, 933-939 (2010).
32. Barth, E. et al. Glucose metabolism and catecholamines. Crit. Care Med. 35, S508-S518 (2007).
33. Guhan, A.R. et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55, 650-656 (2000).
34. Patel, R. et al. LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J. Clin. Invest. 121, 431-441 (2011).
35. Vegiopoulos, A. & Herzig, S. Glucocorticoids, metabolism and metabolic diseases. Mol. Cell. Endocrinol. 275, 43-61 (2007).
36. Tulipano, G. et al. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 85, 61-70 (2007).
37. Smith, G.C., Chaussade, C., Vickers, M., Jensen, J. & Shepherd, P.R. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51, 2309-2317 (2008).
38. Newcomer, J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (suppl. 1), 1-93 (2005).
39. Joost, H.G., Poser, W. & Panten, U. Inhibition of insulin release from the rat pancreas by cyproheptadine and tricyclic antidepressants. Naunyn Schmiedebergs Arch. Pharmacol. 285, 99-102 (1974).
40. Gupta, B., Shakarwal, M.K., Kumar, A. & Jaju, B.P. Modulation of glucose homeostasis by doxepin. Methods Find. Exp. Clin. Pharmacol. 14, 61-71 (1992).
41. Pan, A. et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 55, 63-72 (2012).
42. Srinivasan, S. et al. Serotonin regulates C. elegans fat and feeding through independent molecular mechanisms. Cell Metab. 7, 533-544 (2008).
43. Ye, Z. et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS ONE 6, e21551 (2011).
44. Andersohn, F., Schade, R., Suissa, S. & Garbe, E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am. J. Psychiatry 166, 591-598 (2009).
45. Thermes, V. et al. I-SceI meganuclease mediates highly efficient transgenesis in fish. Mech. Dev. 118, 91-98 (2002).
46. Jurczyk, A. et al. Dynamic glucoregulation and mammalian-like responses to metabolic and developmental disruption in zebrafish. Gen. Comp. Endocrinol. 170, 334-345 (2011).
47. Her, G.M., Yeh, Y.-H. & Wu, J.-L. 435-bpliver regulatory sequence in the liver fatty acid binding protein (L-FABP) gene is sufficient to modulate liver regional expression in transgenic zebrafish. Dev. Dyn. 227, 347-356 (2003).
48. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
49. Finck, B.N. et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway. Cell Metab. 4, 199-210 (2006).
50. Hirschey, M.D. et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell 44, 177-190 (2011).
51. Thisse, C. & Thisse, B. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat. Protoc. 3, 59-69 (2008).